L-Kynurenine participates in cancer immune evasion by downregulating hypoxic signaling in T lymphocytes

References

• Kyrysyuk O, Wucherpfennig KW. Designing cancer immunotherapies that engage T Cells and NK Cells. Annu Rev Immunol. 2023;41(1):17–14. doi:10.1146/annurev-immunol-101921-044122.
   PubMedGoogle Scholar
• Schlichtner S, Yasinska IM, Ruggiero S, Berger SM, Aliu N, Prunk M, Kos J, Meyer NH, Gibbs BF, Fasler-Kan E, et al. ExpressiOn of the immune checkpoint protein VISTA is differentially regulated by the TGF-beta1 - Smad3 signaling pathway in rapidly proliferating human cells and T lymphocytes. Front Med. 2022;9:790995. doi:10.3389/fmed.2022.790995.
   Web of Science ®Google Scholar
• Selnø ATH, Schlichtner S, Yasinska IM, Sakhnevych SS, Fiedler W, Wellbrock J, Klenova E, Pavlova L, Gibbs BF, Degen M, et al. Transforming growth factor beta type 1 (TGF-beta) and hypoxia-inducible factor 1 (HIF-1) transcription complex as master regulators of the immunosuppressive protein galectin-9 expression in human cancer and embryonic cells. Aging. 2020;12:23478–23496. doi:10.18632/aging.202343.
   PubMedGoogle Scholar
• Yang R, Sun L, Li CF, Wang YH, Yao J, Li H, Yan M, Chang WC, Hsu JM, Cha JH, et al. Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy. Nat Commun. 2021;12(1):832. doi: 10.1038/s41467-021-21099-2.
   PubMed Web of Science ®Google Scholar
• Yasinska IM, Gonçalves Silva I, Sakhnevych SS, Ruegg L, Hussain R, Siligardi G, Fiedler W, Wellbrock J, Bardelli M, Varani L, et al. High mobility group box 1 (HMGB1) acts as an “alarmin” to promote acute myeloid leukaemia progression. OncoImmunology. 2018a;7(6):e1438109. doi:10.1080/2162402X.2018.1438109.
   PubMed Web of Science ®Google Scholar
• Yasinska IM, Meyer NH, Schlichtner S, Hussain R, Siligardi G, Casely-Hayford M, Fiedler W, Wellbrock J, Desmet C, Calzolai L, et al. Ligand-receptor interactions of galectin-9 and VISTA suppress human T lymphocyte cytotoxic activity. Front Immunol. 2020;11:580557. doi:10.3389/fimmu.2020.580557.
   PubMed Web of Science ®Google Scholar
• El-Fattah EEA. IDO/Kynurenine pathway in cancer: possible therapeutic approaches. J Transl Med. 2022;20(1):347. doi:10.1186/s12967-022-03554-w.
   PubMed Web of Science ®Google Scholar
• Mezrich JD, Fechner JH, Zhang X, Johnson BP, Burlingham WJ, Bradfield CA. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol. 2010;185(6):3190–3198. doi:10.4049/jimmunol.0903670.
   PubMed Web of Science ®Google Scholar
• Badawy AA-B. Kynurenine pathway of tryptophan metabolism: regulatory and functional aspects. International Journal Of Tryptophan Research. 2017;10:1178646917691938. doi:10.1177/1178646917691938.
   Web of Science ®Google Scholar
• Zhai L, Ladomersky E, Bell A, Dussold C, Cardoza K, Qian J, Lauing KL, Wainwright DA. Quantification of IDO1 enzyme activity in normal and malignant tissues. Methods Enzymol. 2019;629:235–256.
   PubMed Web of Science ®Google Scholar
• Tan VX, Guillemin GJ. Kynurenine pathway metabolites as biomarkers for amyotrophic lateral sclerosis. Front Neurosci. 2019;13:1013. doi:10.3389/fnins.2019.01013.
   PubMed Web of Science ®Google Scholar
• Sorgdrager FJH, Naude PJW, Kema IP, Nollen EA, Deyn PP. TryptopHan metabolism in inflammaging: from biomarker to therapeutic target. Front Immunol. 2019;10:2565. doi:10.3389/fimmu.2019.02565.
   PubMed Web of Science ®Google Scholar
• Song H, Park H, Kim YS, Kim KD, Lee HK, Cho DH, Yang JW, Hur DY. L-kynurenine-induced apoptosis in human NK cells is mediated by reactive oxygen species. Int Immunopharmacol. 2011;11(8):932–938. doi:10.1016/j.intimp.2011.02.005.
   PubMed Web of Science ®Google Scholar
• Semenza GL. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med. 2002;8(4):S62–67. doi:10.1016/S1471-4914(02)02317-1.
   PubMed Web of Science ®Google Scholar
• Ochs K, Ott M, Rauschenbach KJ, Deumelandt K, Sahm F, Opitz CA, von Deimling A, Wick W, Platten M. Tryptophan-2,3-dioxygenase is regulated by prostaglandin E2 in malignant glioma via a positive signaling loop involving prostaglandin E receptor-4. J Neurochem. 2016;136(6):1142–1154. doi:10.1111/jnc.13503.
   PubMed Web of Science ®Google Scholar
• Opitz CA, Litzenburger UM, Opitz U, Sahm F, Ochs K, Lutz C, Wick W, Platten M, Oresic M. The indoleamine-2,3-dioxygenase (IDO) inhibitor 1-methyl-D-tryptophan upregulates IDO1 in human cancer cells. PLoS One. 2011;6(5):e19823. doi:10.1371/journal.pone.0019823.
   PubMed Web of Science ®Google Scholar
• Prokhorov A, Gibbs BF, Bardelli M, Ruegg L, Fasler-Kan E, Varani L, Sumbayev VV. The immune receptor Tim-3 mediates activation of PI3 kinase/mTOR and HIF-1 pathways in human myeloid leukaemia cells. Int J Biochem Cell Biol. 2015;59:11–20. doi:10.1016/j.biocel.2014.11.017.
   PubMed Web of Science ®Google Scholar
• Watcharanurak K, Zang L, Nishikawa M, Yoshinaga K, Yamamoto Y, Takahashi Y, Ando M, Saito K, Watanabe Y, Takakura Y. Effects of upregulated indoleamine 2, 3-dioxygenase 1 by interferon γ gene transfer on interferon γ-mediated antitumor activity. Gene Ther. 2014;21(9):794–801. doi:10.1038/gt.2014.54.
   PubMed Web of Science ®Google Scholar
• Chen W, Frank ME, Jin W, Wahl SM. TGF-beta released by apoptotic T cells contributes to an immunosuppressive milieu. Immunity. 2001;14:715–725. doi:10.1016/S1074-7613(01)00147-9.
   PubMed Web of Science ®Google Scholar
• Schlichtner S, Yasinska IM, Lall GS, Berger SM, Ruggiero S, Cholewa D, Aliu N, Gibbs BF, Fasler-Kan E, Sumbayev VV. T lymphocytes induce human cancer cells derived from solid malignant tumors to secrete galectin-9 which facilitates immunosuppression in cooperation with other immune checkpoint proteins. J Immunother Cancer. 2023;11. doi:10.1136/jitc-2022-005714.
   PubMed Web of Science ®Google Scholar
• Gonçalves Silva I, Ruegg L, Gibbs BF, Bardelli M, Fruehwirth A, Varani L, Berger SM, Fasler-Kan E, Sumbayev VV. The immune receptor Tim-3 acts as a trafficker in a Tim-3/galectin-9 autocrine loop in human myeloid leukemia cells. Oncoimmunology. 2016;5(7):e1195535. doi:10.1080/2162402X.2016.1195535.
   PubMed Web of Science ®Google Scholar
• Ala M. The footprint of kynurenine pathway in every cancer: a new target for chemotherapy. Eur J Pharmacol. 2021;896:173921. doi:10.1016/j.ejphar.2021.173921.
   PubMed Web of Science ®Google Scholar
• Newman AC, Falcone M, Huerta Uribe A, Zhang T, Athineos D, Pietzke M, Vazquez A, Blyth K, Maddocks ODK. Immune-regulated IDO1-dependent tryptophan metabolism is source of one-carbon units for pancreatic cancer and stellate cells. Mol Cell. 2021;81:2290–2302 e2297. doi:10.1016/j.molcel.2021.03.019.
   PubMed Web of Science ®Google Scholar
• Gonçalves Silva I, Yasinska IM, Sakhnevych SS, Fiedler W, Wellbrock J, Bardelli M, Varani L, Hussain R, Siligardi G, Ceccone G, et al. The tim-3-galectin-9 secretory pathway is involved in the immune escape of human acute myeloid leukemia cells. EBioMedicine. 2017;22:44–57. doi:10.1016/j.ebiom.2017.07.018.
   PubMed Web of Science ®Google Scholar
• Teo Hansen Selnø A, Schlichtner S, Yasinska IM, Sakhnevych SS, Fiedler W, Wellbrock J, Berger SM, Klenova E, Gibbs BF, Fasler-Kan E, Sumbayev VV. 2021. High Mobility Group Box 1 (HMGB1) induces toll-like receptor 4-mediated production of the immunosuppressive protein galectin-9 in human cancer cells. Frontiers in Immunology 12: 675731
   Google Scholar
• Yasinska IM, Gonçalves Silva I, Sakhnevych S, Gibbs BF, Raap U, Fasler-Kan E, Sumbayev VV. Biochemical mechanisms implemented by human acute myeloid leukemia cells to suppress host immune surveillance. Cell Mol Immunol. 2018b;15(11):989–991. doi:10.1038/s41423-018-0047-6.
   PubMed Web of Science ®Google Scholar
• Gajanayaka N, Dong SXM, Ali H, Iqbal S, Mookerjee A, Lawton DA, Caballero RE, Cassol E, Cameron DW, Angel JB, et al. TLR-4 agonist induces IFN-gamma production selectively in proinflammatory human M1 macrophages through the PI3K-Mtor- and JNK-MAPK-activated p70S6K pathway. J Immunol. 2021;207:2310–2324. doi:10.4049/jimmunol.2001191.
   PubMed Web of Science ®Google Scholar
• Kraaij MD, Vereyken EJ, Leenen PJ, van den Bosch TP, Rezaee F, Betjes MG, Baan CC, Rowshani AT. Human monocytes produce interferon-gamma upon stimulation with LPS. Cytokine. 2014;67(1):7–12. doi:10.1016/j.cyto.2014.02.001.
   PubMed Web of Science ®Google Scholar
• Kanevskiy LM, Telford WG, Sapozhnikov AM, Kovalenko EI. Lipopolysaccharide induces IFN-γ production in human NK cells. Front Immunol. 2013;4:11. doi:10.3389/fimmu.2013.00011.
   PubMed Web of Science ®Google Scholar
• Stock C, Ambros IM, Lion T, Zoubek A, Amann G, Gadner H, Ambros PF. Genetic changes of two Wilms tumors with anaplasia and a review of the literature suggesting a marker profile for therapy resistance. Cancer Genet Cytogenet. 2002;135(2):128–138. doi:10.1016/S0165-4608(01)00647-1.
   PubMedGoogle Scholar
• Yasinska IM, Sakhnevych SS, Pavlova L, Teo Hansen Selnø A, Teuscher Abeleira AM, Benlaouer O, Gonçalves Silva I, Mosimann M, Varani L, Bardelli M, et al. ThE tim-3-galectin-9 pathway and its regulatory mechanisms in human breast cancer. Front Immunol. 2019;10:1594. doi:10.3389/fimmu.2019.01594.
   PubMed Web of Science ®Google Scholar